Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Medline, Inc. Class A (MDLN) and Silence Therapeutics (SLN)

Tipranks - Tipranks - Fri Feb 27, 6:12AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Schrodinger (SDGR – Research Report), Medline, Inc. Class A (MDLN – Research Report) and Silence Therapeutics (SLN – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Schrodinger (SDGR)

Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on Schrodinger today and set a price target of $20.00. The company’s shares closed last Wednesday at $11.80.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 2.4% and a 51.9% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Schrodinger with a $21.20 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Medline, Inc. Class A (MDLN)

Bank of America Securities analyst Andrew Obin reiterated a Buy rating on Medline, Inc. Class A today and set a price target of $55.00. The company’s shares closed last Wednesday at $48.18.

According to TipRanks.com, Obin is a top 100 analyst with an average return of 19.8% and a 69.1% success rate. Obin covers the Industrial Goods sector, focusing on stocks such as Emerson Electric Company, Honeywell International, and Illinois Tool Works. ;'>

Medline, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $49.04, which is a 3.5% upside from current levels. In a report issued on February 12, Evercore ISI also maintained a Buy rating on the stock with a $50.00 price target.

Silence Therapeutics (SLN)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Silence Therapeutics yesterday and set a price target of $75.00. The company’s shares closed last Wednesday at $5.35, close to its 52-week low of $3.19.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 25.4% and a 48.4% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

Currently, the analyst consensus on Silence Therapeutics is a Moderate Buy with an average price target of $75.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).